HOUSTON and AUSTIN, Texas, Aug. 7 /PRNewswire-FirstCall/ -- David G. Nance, co-founder and Chief Executive Officer of Introgen Therapeutics, Inc. has been presented with the 2006 Albert Einstein Award for Outstanding Achievement in the Life Sciences. Mr. Nance received the award for his work in developing new cancer therapies which unlock the body’s molecular cancer defense mechanisms to spare cancer patients from the devastating side effects of conventional cancer treatments.
(Photo: http://www.newscom.com/cgi-bin/prnh/20060807/DAM011 )
“I want to know how God created this world ... I want to know His thoughts, the rest are details.” This statement of Albert Einstein reflects his uninhibited curiosity and ingeniousness that led him to monumental achievements. It is also what drives the recipients of a tribute bearing the great scientist’s name, the Albert Einstein Award for Outstanding Achievement in the Life Sciences.
Previous recipients of the prestigious Albert Einstein Award for Outstanding Achievement in the Life Sciences include Francis Collins, the Director of the National Human Genome Research Institute. Other 2006 Einstein award recipients included James Rothman, Professor of Physiology & Cellular Biophysics at Columbia University College of Physicians and Surgeons and George Poste, Director of the Biodesign Institute at Arizona State University. The Albert Einstein Award was presented at a June 2006 ceremony in Jerusalem by Former Prime Minister Benjamin Netanyahu, after remarks by Deputy Prime Minister Shimon Peres. The award is given annually by the Global Business Leadership Council to individuals whose vision and commitment have contributed to the critical advancement of life-saving and life-enhancing technology.
David Nance commented, “I share this honor with colleagues striving to improve the lives of cancer patients. Einstein’s profound gift was to connect seemingly diverse elements to explanations of universal systems. We are trying to apply similar principles to connect elements of biological systems. I am humbled to receive an award named for one of my heroes.”
About Introgen Therapeutics, Inc.
Introgen Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted molecular therapies for the treatment of cancer and other diseases. Introgen is developing molecular therapeutics, immunotherapies and nano-particle therapies to treat a wide range of cancers using tumor suppressors and cytokines. Introgen maintains integrated research, development, manufacturing, clinical and regulatory departments and operates multiple manufacturing facilities including a commercial scale cGMP manufacturing facility.
Statements in this release that are not strictly historical may be “forward-looking” statements, including those relating to Introgen’s future success with its clinical development programs for treatment of cancer or other diseases. The actual results may differ from those described in this release due to risks and uncertainties that exist in Introgen’s operations and business environment, including Introgen’s stage of product development and the limited experience in the development of gene-based drugs in general, dependence upon proprietary technology and the current competitive environment, history of operating losses and accumulated deficits, reliance on collaborative relationships, and uncertainties related to clinical trials, the safety and efficacy of Introgen’s product candidates, the ability to obtain the appropriate regulatory approvals, Introgen’s patent protection and market acceptance, as well as other risks detailed from time to time in Introgen’s filings with the Securities and Exchange Commission including its filings on Form 10-K and Form 10-Q. Introgen undertakes no obligation to publicly release the results of any revisions to any forward-looking statements that reflect events or circumstances arising after the date hereof.
Editor’s Note: For more information on Introgen Therapeutics, or for a menu of archived press releases, please visit Introgen’s Website at: http://www.introgen.com .
Contact: Introgen Therapeutics, Inc. C. Channing Burke (512) 708 9310 Ext. 322 Email: c.burke@introgen.com
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20060807/DAM011AP Archive: http://photoarchive.ap.orgPRN Photo Desk, photodesk@prnewswire.comIntrogen Therapeutics, Inc.
CONTACT: C. Channing Burke of Introgen Therapeutics, Inc.,+1-512-708-9310, ext. 322, or c.burke@introgen.com
Web site: http://www.introgen.com/
